Characterization of the CCK-B/gastrin-like receptor in human colon cancer

被引:39
|
作者
Smith, JP [1 ]
Stock, EA [1 ]
Wotring, MG [1 ]
McLaughlin, PJ [1 ]
Zagon, IS [1 ]
机构
[1] PENN STATE UNIV, MILTON S HERSHEY MED CTR, DEPT ANAT & NEUROSCI, HERSHEY, PA 17033 USA
关键词
peptides; L-365,260; antagonist; neoplasia;
D O I
10.1152/ajpregu.1996.271.3.R797
中图分类号
Q4 [生理学];
学科分类号
071003 ;
摘要
The gastrointestinal peptide, gastrin, tonically stimulates growth of human colon cancer cells in vivo and in vitro, and does so in a receptor-mediated fashion. This study defined the nature of gastrin binding in human colon cancer using [H-3]L-365,260, a specific cholecystokinin B (CCK-B)/gastrin antagonist found to block gastrin's effects on growth. Following elucidation of optimal binding conditions (e.g., pH, time, and temperature) in log phase HT-29 human colon cancer cells, specific and saturable binding with a dissociation constant of 4.8 +/- 0.7 nM and a maximal binding capacity (B-max) of 320 +/- 120 fmol/mg protein, consistent with a single binding site, was recorded. Binding was localized to the membrane fraction. Exposure to gastrin or receptor antagonist decreased and increased, respectively, the B-max. Competition experiments indicated that L-365,260 was 25- and 200-fold more effective at displacing radiolabeled L-365,260 than gastrin and cholecystokinin, respectively. In contrast to log phase cells, the B-max was decreased by 67 to 76% in confluent and postconfluent cultures. Binding activity was observed in other cell lines examined, as well as in xenografts and colon cancers obtained at surgery. Binding in normal human colonic mucosa was 10-fold less than in colon cancer. These results provide the first comprehensive identification and characterization of a CCK-B/gastrin-like receptor in human colon cancer.
引用
收藏
页码:R797 / R805
页数:9
相关论文
共 50 条
  • [31] Nuclear expression of an epitope of the CCK-B/gastrin receptor.
    Caplin, ME
    Khan, K
    Michaeli, D
    Lewin, J
    Savage, K
    Watson, SA
    Pounder, RE
    Dhillon, AP
    GASTROENTEROLOGY, 1997, 112 (04) : A1136 - A1136
  • [32] CCK-B/GASTRIN RECEPTOR MEDIATES GASTRIN, CCK BUT NOT HISTAMINE STIMULATING ACID-SECRETION IN RATS
    SONG, Y
    LI, P
    LEE, KY
    CHEY, WY
    GASTROENTEROLOGY, 1994, 106 (04) : A843 - A843
  • [33] IDENTIFICATION AND CHARACTERIZATION OF CCK-B/GASTRIN RECEPTORS IN HUMAN PANCREATIC-CANCER CELL-LINES
    SMITH, JP
    LIU, GZ
    SOUNDARARAJAN, V
    MCLAUGHLIN, PJ
    ZAGON, IS
    AMERICAN JOURNAL OF PHYSIOLOGY, 1994, 266 (01): : R277 - R283
  • [34] Cholecystokinin-13 (CCK-B)/gastrin receptor targeting peptides for staging and therapy of medullary thyroid cancer and other CCK-B receptor expressing malignancies
    Béhé, M
    Behr, TM
    BIOPOLYMERS, 2002, 66 (06) : 399 - 418
  • [35] DEVELOPMENT OF ANTRAL GASTRIN-LIKE IMMUNOREACTIVITY AND PITUITARY CCK8 GASTRIN-LIKE IMMUNOREACTIVITY IN RATS
    OKAHATA, H
    NISHI, Y
    MURAKI, K
    SUMII, K
    TANAKA, K
    MIYACHI, Y
    USUI, T
    EXPERIENTIA, 1985, 41 (07): : 938 - 940
  • [36] Cellular expression of CCK-A and CCK-B/gastrin receptors in human gastric mucosa
    Schmitz, F
    Göke, MN
    Otte, JM
    Schrader, H
    Reimann, B
    Kruse, ML
    Siegel, EG
    Peters, J
    Herzig, KH
    Fölsch, UR
    Schmidt, WE
    REGULATORY PEPTIDES, 2001, 102 (2-3) : 101 - 110
  • [37] A TRUNCATED ISOFORM OF HUMAN CCK-B/GASTRIN RECEPTOR GENERATED BY ALTERNATIVE USAGE OF A NOVEL EXON
    MIYAKE, A
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1995, 208 (01) : 230 - 237
  • [38] CCK/GASTRIN-LIKE IMMUNOREACTIVITY IN BRAIN AND GUT, AND CCK SUPPRESSION OF FEEDING IN GOLDFISH
    HIMICK, BA
    PETER, RE
    AMERICAN JOURNAL OF PHYSIOLOGY, 1994, 267 (03): : R841 - R851
  • [39] Identification of CCK-B/gastrin receptor splice variants in human peripheral blood mononuclear cells
    Schmitz, F
    Schrader, H
    Otte, JM
    Schmitz, H
    Stüber, E
    Herzig, KH
    Schmidt, WE
    REGULATORY PEPTIDES, 2001, 101 (1-3) : 25 - 33
  • [40] Gastrin species and the CCK-B/Gastrin receptor are expressed by gastric pre-malignant lesions
    Henwood, M
    Smith, AM
    Watson, SA
    GASTROENTEROLOGY, 1999, 116 (04) : A420 - A420